Basic Information
Talmanco (previously Tadalafil Generics)
Regulatory Information
EMEA/H/C/004297
January 9, 2017
November 10, 2016
9
April 9, 2025
Company Information
Ireland
Damastown Industrial Park Dublin 15
VIATRIS PHARMA LIMITED
Drug Classification
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Talmanco is indicated in adults for the treatment of pulmonary arterial hypertension (PAH) classified as WHO functional class II and III, to improve exercise capacity. Efficacy has been shown in idiopathic PAH (IPAH) and in PAH related to collagen vascular disease.
Overview Summary
This is a summary of the European public assessment report (EPAR) for Talmanco. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Talmanco. For practical information about using Talmanco, patients should read the package leaflet or contact their doctor or pharmacist.